Download PDF
Thromb Haemost 1997; 77(02): 406-407
DOI: 10.1055/s-0038-1655980
Letter to the Editor
Schattauer GmbH Stuttgart

Successful Clinical Use of a Plasma-derived, Dual Virus Inactivated Factor VIII Concentrate Incorporating Solvent-detergent and Dry Heat Treatment

M P Smith
The Haemophilia Centre, Reference Centre for Haemostatic and Thrombotic Disorders, St Thomas’ Hospital, London
,
K M Rice
The Haemophilia Centre, Reference Centre for Haemostatic and Thrombotic Disorders, St Thomas’ Hospital, London
,
G F Savidge
The Haemophilia Centre, Reference Centre for Haemostatic and Thrombotic Disorders, St Thomas’ Hospital, London
› Author Affiliations
Further Information

Publication History

Received 18 June 1996

Accepted 28 August 1996

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Johnson Z, Thornton L, Tobin A, Lawlor E, Power J, Hillary I, Temperley I. An outbreak of hepatitis A among Irish haemophiliacs. International Journal of Epidemiology 1995; 24: 821-828
    CrossrefPubMedGoogle Scholar
  • 2 Rosendaal FR, Nieuwenhuis HK, van denBerg HM, Heijboer H, Mauser-Bunschoten EP, van denMeer J, Smith C, Strangers PFW, Briët E. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81: 2180-2186
    PubMedGoogle Scholar
  • 3 Ristol P, Gensana M, Fernandez J, Massot M, Biescas H, Darling A, Jorquera JI, Vericat F. Estudio de validacion de la seguridad viral de un concentrado terapéutico de factor VIII humano de alta pureza, sometido a dos tratamientos especificos de inactivacion viral (FANHDI®). Sangre 1995; 40 (Suppl. 04) 111
    PubMedGoogle Scholar
  • 4 Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coag Fibrinol 1993; 4: 753-758
    CrossrefPubMedGoogle Scholar
  • 5 Azzi A, Ciappi S, Zakvrzewska K, Morfmi M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. American Journal of Hematology 1992; 39: 228-230
    CrossrefPubMedGoogle Scholar
  • 6 Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S. Human parvovirus B19 infection associated with acute hepatitis. Lancet 1996; 347: 868-869
    CrossrefPubMedGoogle Scholar
  • 7 Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, d’Oiron R, Tchemia G. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Nouvelle Revue Fran9aise d’Hematologie 1994; 36: 449-453
    PubMedGoogle Scholar